Monjuvi brings targeted lymphoma therapy closer to first-line use

Monjuvi is a targeted antibody therapy used to treat certain adults with diffuse large B-cell lymphoma, offering an additional option beyond standard chemotherapy-based regimens for eligible US patients Monjuvi HCP, 03/15/2025.

As of: 05/31/2026 | Reading time: approx. 8 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

What Monjuvi Is and How It Works

Monjuvi is the brand name for tafasitamab-cxix, a CD19-directed cytolytic monoclonal antibody used together with lenalidomide in certain adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant Monjuvi HCP, 03/15/2025.

The medicine is designed to bind to the CD19 antigen on the surface of B cells, including malignant B cells, and may help the immune system recognize and destroy these cells through antibody-dependent cellular cytotoxicity and other mechanisms Monjuvi HCP, 03/15/2025.

In the approved setting, Monjuvi is given as an intravenous infusion on a schedule that is more intensive during the first cycles and then tapers in frequency, in combination with oral lenalidomide for up to twelve cycles and then as monotherapy until disease progression or unacceptable toxicity, according to the US prescribing information Monjuvi HCP, 03/15/2025.

Why Monjuvi Matters for US Consumers and Industry

For US patients with diffuse large B-cell lymphoma who have already received at least one systemic therapy and are not candidates for autologous stem cell transplant, Monjuvi in combination with lenalidomide provides a non-chemotherapy immunotherapy option that can be administered in outpatient infusion centers FDA, 07/31/2020.

The regimen is positioned among other second-line or later therapies for diffuse large B-cell lymphoma, which may include CAR T-cell products, chemotherapy combinations, or other antibody-based regimens, giving clinicians another evidence-based option to tailor treatment based on patient fitness, comorbidities, and logistical considerations AJMC, 05/30/2026.

For the biopharmaceutical industry, Monjuvi illustrates how targeted antibodies against B-cell antigens can be used in rational combinations with immunomodulatory drugs, potentially expanding the range of patients who can benefit from immunotherapy without requiring individualized cell collection and engineering.

Monjuvi in the US and Global Market

In the United States, Monjuvi is commercialized by Incyte and is available in hematology and oncology clinics that treat adults with lymphoma, with access usually coordinated through specialty pharmacies and hospital infusion services that manage prior authorization and reimbursement processes Incyte, 03/10/2025.

Outside the United States, tafasitamab is marketed as Minjuvi in certain regions, reflecting regulatory approvals obtained in collaboration between MorphoSys and Incyte for relapsed or refractory diffuse large B-cell lymphoma in adults who are not candidates for autologous stem cell transplant MorphoSys, 03/05/2025.

Recent clinical trial data from the frontMIND study evaluating a tafasitamab-based combination added to an R-CHOP backbone in newly diagnosed diffuse large B-cell lymphoma reported a statistically significant prolongation of progression-free survival compared with R-CHOP alone, suggesting potential relevance for earlier-line treatment decisions once regulators have reviewed the results Business Wire, 05/30/2026.

• CD19-directed monoclonal antibody combined with lenalidomide in adults with certain diffuse large B-cell lymphoma.
• Approved for patients who have received at least one systemic therapy and are not candidates for autologous stem cell transplant in the United States.
• Administered as intravenous infusions on a defined schedule, initially with lenalidomide and later as monotherapy in clinical practice.
• Commercialized in the United States by Incyte, with MorphoSys as a key development partner and Minjuvi branding in selected international markets.

Frequently Asked Questions About Monjuvi

Who is Monjuvi for in the United States?
Monjuvi in combination with lenalidomide is indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant after at least one prior systemic therapy FDA, 07/31/2020.

How is Monjuvi typically administered?
Monjuvi is given as an intravenous infusion on a schedule that is more frequent during the initial cycles, alongside oral lenalidomide for a defined period, and can then continue as monotherapy until disease progression or unacceptable toxicity in accordance with the prescribing information Monjuvi HCP, 03/15/2025.

Is Monjuvi used together with standard chemotherapy?
In routine US practice, the approved use pairs Monjuvi with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma, while investigational studies such as frontMIND are evaluating tafasitamab-containing combinations with R-CHOP in newly diagnosed patients AJMC, 05/30/2026.

Monjuvi was originally developed by MorphoSys in collaboration with Incyte, and the product represents an important commercial and scientific asset for the companies in the field of hematologic oncology.

The issuer behind Monjuvi is MorphoSys AG, identified in capital markets through the ISIN DE0006632003, with Incyte holding commercialization rights in the United States for this oncology product.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.